Severe liver toxicity in postexposure prophylaxis for HIV infection with a zidovudine, lamivudine and fosamprenavir/ritonavir regimen
In France, post-exposure prophylaxis (PEP) is provided to patients after HIV occupational or sexual exposure. Current guidelines recommend the use of combined antiretroviral therapy (i.e. two nucleoside reverse-transcriptase inhibitors and one protease inhibitor) for 4 weeks. After January, 2006, in...
Gespeichert in:
| Veröffentlicht in: | AIDS (London) 2007-01, Vol.21 (2), p.268-269 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 269 |
|---|---|
| container_issue | 2 |
| container_start_page | 268 |
| container_title | AIDS (London) |
| container_volume | 21 |
| creator | Pavel, Simona Burty, Christine Alcaraz, Isabelle de la Tribonnière, Xavier Baclet, Véronique Ajana, Faiza Mouton, Yves Rabaud, Christian Yazdanpanah, Yazdan |
| description | In France, post-exposure prophylaxis (PEP) is provided to patients after HIV occupational or sexual exposure. Current guidelines recommend the use of combined antiretroviral therapy (i.e. two nucleoside reverse-transcriptase inhibitors and one protease inhibitor) for 4 weeks. After January, 2006, in the Infectious Disease Department of Lille University at Tourcoing Hospital, France, in the absence of genotypic resistance mutations to antiretroviral drugs in source patients, PEP provided to patients exposed to HIV was changed from zidovudine/ lamivudine (combivir) 300mg/150mg twice a day, and nelfinavir (1250 mg twice a day) to combivir and fosamprenavir/ritonavir (700/100 mg twice a day). |
| doi_str_mv | 10.1097/QAD.0b013e328011aa35 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_21042552</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>21042552</sourcerecordid><originalsourceid>FETCH-LOGICAL-c351t-44fdd8ca4d6f9e5e624cd8378d749fd2944d203e89a22b4996c1ea175f4a48713</originalsourceid><addsrcrecordid>eNpdkEtPwzAQhH0A0VL4Bwj5xIm2fqWxj1V5tBISQjyukRtvqFESBzspLXf-N4ZWQuKys9LOjLQfQmeUjChR6fhhejUiS0I5cCYJpVrz5AD1CZuooeIp6aHjEN4IIQmR8gj1aEpVKjnvo69HWIMHXNoouHUbm9t2i22NGxda2MTZxXPjXbPalnpjAy6cx_PFS_QUkLfW1fjDtius8ac1bt0ZW8MlLnVldzvWtYmZoKvGQ63X1o-9bd3vhj282grqE3RY6DLA6V4H6Pnm-mk2H97d3y5m07thzhPaDoUojJG5FmZSKEhgwkRuJE-lSYUqDFNCGEY4SKUZWwqlJjkFTdOkEFrIlPIButj1xn_eOwhtVtmQQ1nqGlwXMkaJYEnColHsjLl3IXgossbbSvttRkn2gzyLyLP_yGPsfN_fLSswf6E9b_4NxYeDgw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>21042552</pqid></control><display><type>article</type><title>Severe liver toxicity in postexposure prophylaxis for HIV infection with a zidovudine, lamivudine and fosamprenavir/ritonavir regimen</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Pavel, Simona ; Burty, Christine ; Alcaraz, Isabelle ; de la Tribonnière, Xavier ; Baclet, Véronique ; Ajana, Faiza ; Mouton, Yves ; Rabaud, Christian ; Yazdanpanah, Yazdan</creator><creatorcontrib>Pavel, Simona ; Burty, Christine ; Alcaraz, Isabelle ; de la Tribonnière, Xavier ; Baclet, Véronique ; Ajana, Faiza ; Mouton, Yves ; Rabaud, Christian ; Yazdanpanah, Yazdan</creatorcontrib><description>In France, post-exposure prophylaxis (PEP) is provided to patients after HIV occupational or sexual exposure. Current guidelines recommend the use of combined antiretroviral therapy (i.e. two nucleoside reverse-transcriptase inhibitors and one protease inhibitor) for 4 weeks. After January, 2006, in the Infectious Disease Department of Lille University at Tourcoing Hospital, France, in the absence of genotypic resistance mutations to antiretroviral drugs in source patients, PEP provided to patients exposed to HIV was changed from zidovudine/ lamivudine (combivir) 300mg/150mg twice a day, and nelfinavir (1250 mg twice a day) to combivir and fosamprenavir/ritonavir (700/100 mg twice a day).</description><identifier>ISSN: 0269-9370</identifier><identifier>DOI: 10.1097/QAD.0b013e328011aa35</identifier><identifier>PMID: 17197833</identifier><language>eng</language><publisher>England</publisher><subject>Adult ; Anti-HIV Agents - adverse effects ; Antiretroviral Therapy, Highly Active - adverse effects ; Chemical and Drug Induced Liver Injury - etiology ; Female ; HIV Infections - prevention & control ; Human immunodeficiency virus ; Humans ; Male</subject><ispartof>AIDS (London), 2007-01, Vol.21 (2), p.268-269</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c351t-44fdd8ca4d6f9e5e624cd8378d749fd2944d203e89a22b4996c1ea175f4a48713</citedby><cites>FETCH-LOGICAL-c351t-44fdd8ca4d6f9e5e624cd8378d749fd2944d203e89a22b4996c1ea175f4a48713</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17197833$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pavel, Simona</creatorcontrib><creatorcontrib>Burty, Christine</creatorcontrib><creatorcontrib>Alcaraz, Isabelle</creatorcontrib><creatorcontrib>de la Tribonnière, Xavier</creatorcontrib><creatorcontrib>Baclet, Véronique</creatorcontrib><creatorcontrib>Ajana, Faiza</creatorcontrib><creatorcontrib>Mouton, Yves</creatorcontrib><creatorcontrib>Rabaud, Christian</creatorcontrib><creatorcontrib>Yazdanpanah, Yazdan</creatorcontrib><title>Severe liver toxicity in postexposure prophylaxis for HIV infection with a zidovudine, lamivudine and fosamprenavir/ritonavir regimen</title><title>AIDS (London)</title><addtitle>AIDS</addtitle><description>In France, post-exposure prophylaxis (PEP) is provided to patients after HIV occupational or sexual exposure. Current guidelines recommend the use of combined antiretroviral therapy (i.e. two nucleoside reverse-transcriptase inhibitors and one protease inhibitor) for 4 weeks. After January, 2006, in the Infectious Disease Department of Lille University at Tourcoing Hospital, France, in the absence of genotypic resistance mutations to antiretroviral drugs in source patients, PEP provided to patients exposed to HIV was changed from zidovudine/ lamivudine (combivir) 300mg/150mg twice a day, and nelfinavir (1250 mg twice a day) to combivir and fosamprenavir/ritonavir (700/100 mg twice a day).</description><subject>Adult</subject><subject>Anti-HIV Agents - adverse effects</subject><subject>Antiretroviral Therapy, Highly Active - adverse effects</subject><subject>Chemical and Drug Induced Liver Injury - etiology</subject><subject>Female</subject><subject>HIV Infections - prevention & control</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Male</subject><issn>0269-9370</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkEtPwzAQhH0A0VL4Bwj5xIm2fqWxj1V5tBISQjyukRtvqFESBzspLXf-N4ZWQuKys9LOjLQfQmeUjChR6fhhejUiS0I5cCYJpVrz5AD1CZuooeIp6aHjEN4IIQmR8gj1aEpVKjnvo69HWIMHXNoouHUbm9t2i22NGxda2MTZxXPjXbPalnpjAy6cx_PFS_QUkLfW1fjDtius8ac1bt0ZW8MlLnVldzvWtYmZoKvGQ63X1o-9bd3vhj282grqE3RY6DLA6V4H6Pnm-mk2H97d3y5m07thzhPaDoUojJG5FmZSKEhgwkRuJE-lSYUqDFNCGEY4SKUZWwqlJjkFTdOkEFrIlPIButj1xn_eOwhtVtmQQ1nqGlwXMkaJYEnColHsjLl3IXgossbbSvttRkn2gzyLyLP_yGPsfN_fLSswf6E9b_4NxYeDgw</recordid><startdate>20070111</startdate><enddate>20070111</enddate><creator>Pavel, Simona</creator><creator>Burty, Christine</creator><creator>Alcaraz, Isabelle</creator><creator>de la Tribonnière, Xavier</creator><creator>Baclet, Véronique</creator><creator>Ajana, Faiza</creator><creator>Mouton, Yves</creator><creator>Rabaud, Christian</creator><creator>Yazdanpanah, Yazdan</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T2</scope><scope>7T5</scope><scope>7U2</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope></search><sort><creationdate>20070111</creationdate><title>Severe liver toxicity in postexposure prophylaxis for HIV infection with a zidovudine, lamivudine and fosamprenavir/ritonavir regimen</title><author>Pavel, Simona ; Burty, Christine ; Alcaraz, Isabelle ; de la Tribonnière, Xavier ; Baclet, Véronique ; Ajana, Faiza ; Mouton, Yves ; Rabaud, Christian ; Yazdanpanah, Yazdan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c351t-44fdd8ca4d6f9e5e624cd8378d749fd2944d203e89a22b4996c1ea175f4a48713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adult</topic><topic>Anti-HIV Agents - adverse effects</topic><topic>Antiretroviral Therapy, Highly Active - adverse effects</topic><topic>Chemical and Drug Induced Liver Injury - etiology</topic><topic>Female</topic><topic>HIV Infections - prevention & control</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Male</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pavel, Simona</creatorcontrib><creatorcontrib>Burty, Christine</creatorcontrib><creatorcontrib>Alcaraz, Isabelle</creatorcontrib><creatorcontrib>de la Tribonnière, Xavier</creatorcontrib><creatorcontrib>Baclet, Véronique</creatorcontrib><creatorcontrib>Ajana, Faiza</creatorcontrib><creatorcontrib>Mouton, Yves</creatorcontrib><creatorcontrib>Rabaud, Christian</creatorcontrib><creatorcontrib>Yazdanpanah, Yazdan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Safety Science and Risk</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>AIDS (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pavel, Simona</au><au>Burty, Christine</au><au>Alcaraz, Isabelle</au><au>de la Tribonnière, Xavier</au><au>Baclet, Véronique</au><au>Ajana, Faiza</au><au>Mouton, Yves</au><au>Rabaud, Christian</au><au>Yazdanpanah, Yazdan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Severe liver toxicity in postexposure prophylaxis for HIV infection with a zidovudine, lamivudine and fosamprenavir/ritonavir regimen</atitle><jtitle>AIDS (London)</jtitle><addtitle>AIDS</addtitle><date>2007-01-11</date><risdate>2007</risdate><volume>21</volume><issue>2</issue><spage>268</spage><epage>269</epage><pages>268-269</pages><issn>0269-9370</issn><abstract>In France, post-exposure prophylaxis (PEP) is provided to patients after HIV occupational or sexual exposure. Current guidelines recommend the use of combined antiretroviral therapy (i.e. two nucleoside reverse-transcriptase inhibitors and one protease inhibitor) for 4 weeks. After January, 2006, in the Infectious Disease Department of Lille University at Tourcoing Hospital, France, in the absence of genotypic resistance mutations to antiretroviral drugs in source patients, PEP provided to patients exposed to HIV was changed from zidovudine/ lamivudine (combivir) 300mg/150mg twice a day, and nelfinavir (1250 mg twice a day) to combivir and fosamprenavir/ritonavir (700/100 mg twice a day).</abstract><cop>England</cop><pmid>17197833</pmid><doi>10.1097/QAD.0b013e328011aa35</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-9370 |
| ispartof | AIDS (London), 2007-01, Vol.21 (2), p.268-269 |
| issn | 0269-9370 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_21042552 |
| source | MEDLINE; Journals@Ovid Complete; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Anti-HIV Agents - adverse effects Antiretroviral Therapy, Highly Active - adverse effects Chemical and Drug Induced Liver Injury - etiology Female HIV Infections - prevention & control Human immunodeficiency virus Humans Male |
| title | Severe liver toxicity in postexposure prophylaxis for HIV infection with a zidovudine, lamivudine and fosamprenavir/ritonavir regimen |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T02%3A15%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Severe%20liver%20toxicity%20in%20postexposure%20prophylaxis%20for%20HIV%20infection%20with%20a%20zidovudine,%20lamivudine%20and%20fosamprenavir/ritonavir%20regimen&rft.jtitle=AIDS%20(London)&rft.au=Pavel,%20Simona&rft.date=2007-01-11&rft.volume=21&rft.issue=2&rft.spage=268&rft.epage=269&rft.pages=268-269&rft.issn=0269-9370&rft_id=info:doi/10.1097/QAD.0b013e328011aa35&rft_dat=%3Cproquest_cross%3E21042552%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=21042552&rft_id=info:pmid/17197833&rfr_iscdi=true |